Nuclear Medicine Imaging in the Evaluation of Endocrine Hypertension

Overview

Journal Indian J Endocrinol Metab

Specialty Endocrinology

Date 2012 Oct 23

PMID 23087853

Authors

Punit Sharma

Rakesh Kumar

Affiliations

Soon will be listed here.

Abstract

Endocrine hypertension forms a small (< 5%) but curable subset of patients with hypertension. Common endocrine causes of hypertension include pheochromocytoma, Cushing's syndrome, primary hyperaldosteronism, and thyroid disorders. Nuclear medicine imaging plays an important role in evaluation of patients with endocrine hypertension. It has established role in patients of pheochromocytoma/paraganglioma, Cushing's syndrome, aldosteronism, and thyroid disorders. We present a brief overview of role of nuclear medicine imaging in endocrine hypertension. Development of newer radiotracers might further broaden the role of nuclear medicine in these patients.

References

Xu H, Zhang M, Zhai G, Zhang M, Ning G, Li B . The role of integrated (18)F-FDG PET/CT in identification of ectopic ACTH secretion tumors. Endocrine. 2009; 36(3):385-91. DOI: 10.1007/s12020-009-9247-2. View

Taieb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe C . The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf). 2008; 69(4):580-6. DOI: 10.1111/j.1365-2265.2008.03257.x. View

Gross M, Valk T, Swanson D, Thrall J, Grekin R, Beirewaltes W . The role of parmacologic manipulation in adrenal cortical scintigraphy. Semin Nucl Med. 1981; 11(2):128-48. DOI: 10.1016/s0001-2998(81)80042-6. View

Chen Y, Su Y, Wei C, Chiu J, Tseng C, Chen S . Diagnostic value of I-131 NP-59 SPECT/CT scintigraphy in patients with subclinical or atypical features of primary aldosteronism. J Biomed Biotechnol. 2011; 2011:209787. PMC: 3085291. DOI: 10.1155/2011/209787. View

Eisenhofer G . The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther. 2001; 91(1):35-62. DOI: 10.1016/s0163-7258(01)00144-9. View

Fiebrich H, Brouwers A, Kerstens M, Pijl M, Kema I, de Jong J . 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine.... J Clin Endocrinol Metab. 2009; 94(10):3922-30. DOI: 10.1210/jc.2009-1054. View

Young W . Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007; 66(5):607-18. DOI: 10.1111/j.1365-2265.2007.02775.x. View

Fukuoka M, Taki J, Mochizuki T, Kinuya S . Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma. Clin Nucl Med. 2010; 36(1):1-7. DOI: 10.1097/RLU.0b013e3181feeb5e. View

Limouris G, Giannakopoulos V, Stavraka A, Toubanakis N, Vlahos L . Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors. Anticancer Res. 1997; 17(3B):1589-92. View

10.

Mayo-Smith W, Boland G, Noto R, Lee M . State-of-the-art adrenal imaging. Radiographics. 2001; 21(4):995-1012. DOI: 10.1148/radiographics.21.4.g01jl21995. View

11.

Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M . Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. Q J Nucl Med. 1995; 39(4 Suppl 1):145-9. View

12.

Lynn M, Shapiro B, Sisson J, Swanson D, Mangner T, Wieland D . Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I]iodobenzylguanidine: concise communication. J Nucl Med. 1984; 25(4):436-40. View

13.

Timmers H, Chen C, Carrasquillo J, Whatley M, Ling A, Havekes B . Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009; 94(12):4757-67. PMC: 2795662. DOI: 10.1210/jc.2009-1248. View

14.

Sisson J, Frager M, Valk T, Gross M, Swanson D, Wieland D . Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981; 305(1):12-7. DOI: 10.1056/NEJM198107023050103. View

15.

Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I . Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology. 2002; 222(2):507-12. DOI: 10.1148/radiol.2222010622. View

16.

Pacak K, Eisenhofer G, Carrasquillo J, Chen C, Li S, Goldstein D . 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension. 2001; 38(1):6-8. DOI: 10.1161/01.hyp.38.1.6. View

17.

van der Harst E, de Herder W, Bruining H, Bonjer H, de Krijger R, Lamberts S . [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001; 86(2):685-93. DOI: 10.1210/jcem.86.2.7238. View

18.

Hennings J, Sundin A, Hagg A, Hellman P . 11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism. Langenbecks Arch Surg. 2010; 395(7):963-7. DOI: 10.1007/s00423-010-0681-7. View

19.

Lockhart M, Smith J, Kenney P . Imaging of adrenal masses. Eur J Radiol. 2002; 41(2):95-112. DOI: 10.1016/s0720-048x(01)00444-2. View

20.

Solanki K, Bomanji J, Moyes J, Mather S, Trainer P, Britton K . A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992; 13(7):513-21. DOI: 10.1097/00006231-199207000-00006. View